Oral therapy protected mice from lethal radiation while sparing cancer treatment
Researchers at the Fralin Biomedical Research Institute at VTC have developed an experimental oral therapy that protected mice from otherwise harmful radiation exposure while preserving radiation's ability to destroy cancer cells, a finding that could ultimately improve cancer treatment and strengthen preparedness for radiological emergencies.
Researchers at the Fralin Biomedical Research Institute at VTC have developed an experimental oral therapy called XOlacta, which protects mice from harmful radiation exposure while preserving its ability to destroy cancer cells. The therapy, published in the September issue of Cancer Letters, involves packaging a therapeutic peptide known as alpha-CT11 inside naturally occurring milk-derived extracellular vesicles.
These vesicles protect the peptide as it passes through the digestive system, allowing for oral administration rather than injection. This innovation addresses the lack of treatments that protect the body from the widespread effects of high-dose radiation exposure, which is a significant concern for both cancer patients undergoing radiation therapy and for public health in the event of accidental or intentional radiation exposure.
Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
